Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway

Investigational New Drugs

Volumn 17, Issue 3, 1999, Pages 241-258

  End, David W ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Farnesyl protein transferase (FPT); MEK; Raf kinase; Ras

Indexed keywords

1,2,3,4,9,9A HEXAHYDRO 2 [2 (2 METHOXYPHENYL) 1 OXO 2 PROPENYL] 9 (4 METHYLPHENYL) 4,9 ETHANO 3AH BENZ[F]ISOINDOLE 3A CARBOXYLIC ACID; 2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 5 [N [5 (2 BENZOXAZOLYL) 1 METHYL 2 [3,4 (METHYLENEDIOXY)PHENYL] 4 PENTENYL] N (2 NAPHTHYLMETHYL)CARBAMOYL] 1,3 DIOXOLANE 2,2,4 TRICARBOXYLIC ACID; ANTISENSE OLIGODEOXYNUCLEOTIDE; ARGLABIN; BZA 2; CGP 69846A; GGTI 297; GGTI 298; GUANINE NUCLEOTIDE BINDING PROTEIN; L 731735; L 778123; LIMONENE; LONAFARNIB; N (8 AMINO 2 BENZYL 5 ISOPROPYL 9 MERCAPTO 3,6 NONADIENOYL)METHIONINE; N [2 [2 (2 AMINO 3 MERCAPTOPROPYLAMINO) 3 METHYLPENTYLOXY] 3 PHENYLPROPIONYL]METHIONINE SULFONE; N [[5 [(2 AMINO 3 MERCAPTOPROPYL)AMINO][1,1' BIPHENYL] 2 YL]CARBONYL]METHIONINE; PROTEIN FARNESYLTRANSFERASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TIPIFARNIB; UNCLASSIFIED DRUG; UO 126;

BONE MARROW SUPPRESSION; CANCER; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; FATIGUE; HUMAN; NEUTROPENIA; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN MODIFICATION; QT INTERVAL; REVIEW; SIGNAL TRANSDUCTION;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOHEXENES; ENZYME INHIBITORS; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; SIGNAL TRANSDUCTION; TERPENES;

EID: 0033375466     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006380320290     Document Type: Review

References (138)

1. Parada LF, Tabin CJ, Shih C, Weinberg R: Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297: 474-478
2. Santos E, Tronick SR, Aaronson SA, Pulciani S, Barbacid M: T24 human bladder carcinoma oncogene is an activated form of the normal human homologue of BALE-and Harvey-MSV transforming genes. Nature 298: 343-347
3. Gibbs JB: Ras C-terminal processing enzymes - New drug targets. Cell 65: 1-4, 1991
4. Barbacid M: ras Genes. Ann Rev Biochem 56: 779-827, 1987
5. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M: Most human carcinomas of the exocrine pancreas contain mutant c-g-ras genes. Cell 53: 549-554, 1988
6. Grunewald K, Lyons J, Frohlich A, Feichtinger H, Weger RA, Schwab G, Janssen JWG, Bartram CR: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer 45: 1037-1041, 1989
7. Forrester K, Concepcion A, Han K, Grizzle WE, Peruch M: Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298-303, 1987
8. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988
9. Reynolds SH, Anna CK, Brown KC, Wiest JS, Beattie EJ, Pro RW, Iglehart D, Anderson MW: Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci (USA) 88: 1085-1089, 1991
10. Knowles MA, Williamson M: Mutation of H-ras is infrequent in bladder cancer: confirmation by single-strand conformation polymorphisms and direct sequencing. Cancer Res 53: 133-139, 1993
11. 2+ on the guanine nucleotide exchange rate of p21N-ras. J Biol Chem 261: 10963-10965, 1986
12. Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA: Association of Sos Pas exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and uansformation. Nature 363: 45-51, 1993
13. Gibbs JB, Sigal IS, Poe M, Scolnick EM: Intrinsic GT-Pase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci (USA) 81: 5704-5708, 1984
14. Trahey M, McCormick F: A cytoplasmic protein stimulates normal N-ras p21 GTPase but does not affect oncogenic mutants. Science 238: 542-545, 1987
15. Gibbs JB, Schaber MD, Allard WJ, Sigal IS, Scolnick EM: Purification of ras GTPase activating protein from bovine brain. Proc Natl Acad Sci 85: 5026-5030, 1988
16. Martin GA, Viskochil D, Bollag G, McCabe PC, Conroy L, Clark R, O'Connell P, Cawthon RM, Innis MA, McCormick F: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell 63: 843-849, 1990
17. Basu TN, Gutman DH, Fletcher JA, Clover TW, Collins FS, Downward J: Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356:713-718, 1992
18. Crews CM, Erikson RL: Extracellular signals and reversible protein phosphorylation: What to make of it all. Cell 74: 215-217, 1993
19. Stokoe D, Macdonald SG, Cadwallader K, Symons M, Hancock JF: Activation of Raf as a result of recruitment to the plasma membrane. Science 264: 463-1467, 1994
20. Moodie SA, Willumsen BM, Weber MJ, Wolfman A: Complexes of ras-GTP with raf-1 and mitogen-activated protein kinase kinase. Science 260: 1658-1661, 1993
21. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, Rapp UR, Avruch J: Raf-1 activates MAP kinase-kinase. Nature 358: 417-421, 1992
22. Adams PD, Parker PJ: Activation of a mitogen-activated protein (MAP) kinase by a MAP kinase-kinase. J Biol Chem 267: 13135-13137, 1992
23. Seger R, Ahn NG, Boulton TC, Ynacopoulos GD, Panaytatos N, Radziejewska E, Ericsson L, Bratlien RL, Cobbs MH, Krebs E: Microtubule-associated protein 2 kinases, ERKI and ERK2, undergo autophosphorylation on both tyrosine and threonine residues: implication for their mechanism of activation. Proc Natl Acad Sci USA 88: 6142-6146, 1991
24. mapk) in fibroblasts. J Cell Biol 122: 1079-1088, 1993
25. Seger R, Krebs EG: The MAPK signaling cascade. FASEB J 9: 726-735, 1995
26. Bonner TI, Kerby SB, Sutrave P, Gunnell MA, Mark G, Rapp UR: Structure and biological acitivty of human homologs of the raf/mil oncogene. Mol Cell Biol 5: 1400-1407, 1985
27. Mansour SJ, Mattan WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG: Transformation of mammalian cells by constitutively active AMP kinase kinase. Science 265: 966-969, 1994
28. Schaap D, van der Wal J, Howe LR, Marshall CJ, van Bitterswijk WJ: A dominant negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic Pas J Biol Chem 268: 20232-20236, 1993
29. Cowley S, Paterson H, Kemp P, Marshall CJ: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77: 841-852, 1994
30. Westwick JK, Cox AD, Der CD, Cobb MH, Hibi M, Karin M, Brenner DA: Onocgenic ras activates c-Jun via a separate pathway from the activation of extracellular signalregulated kinases. Proc Natl Acad Sci 91: 6030-6034, 1994
31. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ: Increasing complexity of ras signaling. Oncogene 17: 1395-1413, 1998
32. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to Pas protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci USA 89: 6403-6407, 1992
33. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ: Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci 87: 3042-3026, 1990
34. Reiss Y, Goldstein JL, Seabra MC, Casey PJ, Brown MS: Inhibition of purified Ras farnesyl:protein transferase by Cys-AAX peptides. Cell 62: 81-88, 1990
35. Gutierrez JL, Magee AI, Marshall CJ, Hancock JF: Post-translational processing of Ras is two step and involves carboxyl-methylation and carboxyterminal proteolysis. EMBO J 8: 1093-1098, 1989
36. Hancock JF, Magee AI, Childs JE, Marshall CJ: All ras proteins are polyisoprenylated but only some ate palmitoylated. Cell 57: 1167-1177, 1989
37. Yokoyama K, McGeady P, Gelb MH: Mammalian protein geranylgeranyltransferase-I: Substrate specificity, kinetic mechanism, metal requirements and affinity labeling. Biochemistry 34: 1344-1354, 1995
38. Otto JC, Kim E, Young SG, Casey PJ: Cloning and characterization of a mammalian prenyl protein-specific protease. J Biol Chem 272: 8379-8382, 1999
39. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ: Isoprenoid addition to Pas protein is the critical modification for its membrane association and transforming activity. Proc Nat'l Acad Sci USA 89: 6403-6407, 1992
40. Park H-W, Boduluri SR, Moomaw JF, Casey PJ, Beese LS: Crystal structure of protein farnesyltransferase at 2.5 angstrom resolution. Science 275: 1800-1804, 1997
41. Dunten P, Kammlot U, Crowther R, Weber D, Palermo R, Birktoft, J: Protein farnesyltransferase: Structure and implications for function. Biochemistry 37: 7907-7912, 1998
42. Reiss Y, Seabra MC, Armstrong SA, Slaughter CA, Goldstein JL, Brown MS: Nonidentical subunits of p21-'as farnesyltransferase. J Biol Chem 266: 10672-10677, 1991
43. Seabra M, Reiss Y, Casey PJ, Brown MS, Goldstein JL: Protein farnesyltransferase and geranylgeranyltransferase share a common et subunit. Cell 66: 429-434, 1991
44. Huang C-C, Casey PJ, Fierke CA: Evidence for catalytic role for zinc in protein farnesyltransferase. J Biol Chem 272: 20-23, 1997
45. Hightower KE, Huang C-C, Casey PJ, Fierke CA: H-ras peprtide substrates bind to protein farnesyltransferase as an ionized thiolate. Biochemistry 37: 15555-15562, 1998
46. Pompliano DL, Schaber MD, Mosser MD, Omer CA, Shafer JA, Gibbs JB: Isoprenoid diphosphate utilization by recombinant human farnesyl:protein transferase: Interactive binding between substrates and a preferred kinetic pathway. Biochemistry 32: 8341-8347, 1993
47. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-rasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270: 6221-6226, 1995
48. SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260: 1934-1937, 1993
49. James CL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters JC: Bentodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animalcells. Science 260: 1937-1939, 1993
50. Garcia AM, Rowell C, Ackerman K, Kowalczyk JJ, Lewis MD: Peptidomimetic inhibitors of ras farnesylation and function in whole cells. J Biol Chem 268: 18415-18418, 1993
51. Kohl NE, Wilson FR, Mosser SD, Giuliani E, de Solms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee T-J, Smith RL, Graham SL, Hartman GD, Gibbs JB, Oliff A: Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc Natl Acad Sci 91: 9141-9145, 1994
52. Sun J, Qian Y, Hamilton AD, Sebti SM: Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of human lung carcinoma with K-ras mutation. Cancer Res 55: 4243-4247, 1995
53. Nagasu T, Yoshimatsu K, Rowell C, Lewis MD, Garcia M: Inhibition of human tumor xenograft growth by treatment with the farnesyl transferase inhibitor B956. Cancer Res 55: 5310-5314, 1995
54. End D, Skrzat SG, Devine A, Angibaud P, Venet M, Sanz G, Bowden C: R115777, a novel imidazole farnesyl protein transferase inhibitor: Biochemical and cellular effects in H-ras and K-ras dominant systems. Proc Am Assoc Cancer Research 39: 269, 1998
55. Zujewksi J, Horak ID, Woestenborghs R, Chiao J, Cusack G, Kohler D, Kremer AB, Cowan KH: Phase I trial of farnesyl transferase inhibitor R115777 in advanced cancer. Proc Am Assoc Cancer Research 39: 269, 1998
56. Schellens JHM, de Klerk G, Swart M, Palmer PA, Bol CJ, van 't Veer LJ, Tan H, ten Bokkel Huinink WW, Beijnen JH: Phase I and pahrmacologic study with the novel farnesyltransferase inhibitor (FTI) R115777. Proc Amer. Assoc. Cancer Research 39:724, 1999
57. Hudes GR, Schol J, Baab J, Rogatko A, Bol K, Horak I, Langer C, Goldstein LJ, Szarka C, Meropol NJ, Weiner L: Phase I clinical and pharmacokinetic trial of the farnesyitransferase inhibitor R115777 on a 21-day dosing schedule. Proc Am Sec Clinical Oncology 601, 1999
58. Adjei AA, Erlichman C, Davis JN, Reid J, Sloan J, Statkevitch P, Zhu Y, Marks RS, Pitot HC, Goldberg R, Hanson L, Alberts S, Cutler D, Kaufman SH: A Phase I and pharmacologic study of the farnesyl protein transferase inhibitor SCH 66336 in patients with locally advanced or metastatic cancer. Proc Am Sec Clinical Oncology 598, 1999
59. Eskens F, Awada J, Verweij DL, Hanauske A, Piccart M: A Phase I and pharmacologic study of the farnesyl protein transferase inhibitor SCH 66336 in patients with solid tumors. Proc Am Sec Clinical Oncology 600, 1999
60. Hurwitz HI, Colvin OM, Petros WP, Williams R, Conway D, Adams DJ, Casey PJ, Calzetta A, Mastoides P, Statkevich P, Cutler D: Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a Zweek on, Zweek off schedule. Proc Am. Sec. Clinical Oncology 599, 1999
61. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielson L, Prioli N, Deli J, Sinha J, Syed J, Korfmacher WA, Nomeir AA, Lin C-C, Wang L, Taveras AG, Doll RJ, Njorge G, Mallams AK, Remisewski S, Catino JJ, Girjavallabahn VM, Kirschmeier P, Bishop WR: Antitumor activity of SCH 6636, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice. Cancer Res 58: 4947-4956, 1998
62. Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, del Rosario J, Deskus J, Mallams AK, Njorge FG, Piwinski JJ, Remiszewski S, Rossman R, Taverase AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK: Tricyclic farnesyl protein transferase inhibitors: Crystallographic and calorimetric studies of structure activity relationships. J Med Chem 42: 2125-2135, 1999
63. Soignet S, Yao S-L, Britten C, Spriggs D, Pezzulli S, McCreery H, Mazina K, Deutsch P, Lee Y, Lobell R, Rosen N, Rowinsky E: Pharmacokinetics and pharmacodynamics of the farnesyl protein transferase inhibitor (L-778,123) in solid tumors. Proc Am Assoc Cancer Res 40: 517, 1998
64. Britten CD, Rowinsky E, Yao S-L, Rosen N, Eckhardt SG, Drengler R, Hammond L, Siu LL, Smith L, McCreery H, Pezzulli S, Lee Y, Lobell R, Deutsch P, Von Hoff D, Spriggs D: The farnesyl protein transferase (FPT) inhibitor L-778,123 in patients with solid cancers. Proc Am Sec Clinical Oncol 597, 1999
65. Todd AV, Applegate TL, Fuery CJ, Roberts NJ, Impey HL, Skrzat SG, End DW: Farnesyl transferase inhibitor(ETTI): effect ofras activation. Proc Am Assoc Cancer Research 39: 317, 1998
66. Kirschmeier P, Carr D, Gray K, James L, Patton R, McGuorck M, Doll RJ, Njorge FG, Taveras A, Remiszewski S, Mallams AK, Kelly J, Girijavallabhan V, Cooper AB, Ganguly AK, Bishop WR: SCH 66336, an orally bioavailable tricyclic farnesyl transferase inhibitor blocks anchorageindependent growth of Pas-transformed fibroblasts and human tumor cell lines. Proc Am Assoc Cancer Research 39: 318, 1998
67. Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Rosen N: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and independent growth of human tumor cell lines. Cancer Res 55: 5302-5309, 1995
68. Smets G, Van Eyck N, Devine A, Bowden C, Wouters W, End DW: R115777, a selective farnesyl protein transferase inhibitor induces predominantly apoptotic activity in C32 melanoma tumor xenografts. Proc Am Assoc Cancer Res 40: 522, 1999
69. Liu M, Lee S, Yaremko B, Dell J, Nielson L, Lipari P, Ferrari E, Malkowski M, Bryant MS, Kirschmeier P, Doll DJ, Njorge FG, Taveras A, Remiszewski S, Mallams AK, Afonso A, Hollinger FP, Cooper AB, Liu Y-T, Rane D, Kelly J, Girjavallabhan V, Cooper AB, Ganguly AK, Bishop W: SCH 66336, an orally active bioavailable tricyclic farnesyl protein transferase inhibitor demonstrates broad and potent in vivo antitumor activity. Proc Am Assoc Cancer Research 39: 269, 1998
70. Skrzat S, Angibaud P, Venet M, Sanz G, Bowden C, End D: R115777, a novel imidazole farnesyl protein transferase inhibitor (FTI) with potent oral antitumor activity. Am Assoc Cancer Res 39: 317, 1998
71. Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, de Solms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K, Handt LK, Hartman GD, Kobaln KS, Kral AM, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Gibbs JB, Oliff A: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nature Medicine 1: 792-797, 19XX
72. Verweij J: Farnesylprotein transferase inhibitors (FTI): Clinical aspects. Proc EORTC Early Drug Development Meeting, June, 1999
73. ras GTPase-activating protein. Proc Natl Acad Sci 89: 1587-1591, 1992
74. Shaikenov TE, Adekenov SM, Baker FL, Prashad N, Williams RM, Sanger LJ: Arglabin inhibits farnesylation of ras protein and cell proliferation. Proc Am Assoc Cancer Res 40: 373, 1999
75. Vrignaud P, Bello A, Bissery MC, Jenkins R, Hasnain A, Maillet P, Lavelle F: RPR 130401, a non-peptidomimetic farnesyltransferase inhibitor with in vivo activity. Proc Am Assoc Cancer Res 39: 270, 1998
76. Vrignaud P, Bissery P, Mailliet MC, Lavelle F: In vivo combination of RPR 130401, a nonpeptidomimetic farnesyltrasnferase inhibitor, with chemotherapy. Am Assoc Cancer Res 40: 523, 1999
77. Yonemoto M, Satoh T, Arakawa H, Suzuki-Takahashi I, Monden Y, Kodera T, Tanaka K, Aoyama T, Iwasawa Y, Kamei T, Nishimura S, Tomimoto K: 5-104,871, a novel farnesyltransferase inhibitor, blocks ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner. Med Pharmacol 54: 1-7, 1998
78. James GL, Goldstein JL, Brown MS: Polylysine and CVIM sequences of K-rasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro. J Biol Chem 270: 6221-6226, 1995
79. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Olivia I, James L, Catino JJ, Bishop WR, Pai J-K: K- and N-ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 272: 14459-14464, 1997
80. Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM: Direct demonstration of geranylgeranylation and farnesylation of Ki-ras in vivo. J Biol Chem 272: 14093-14097, 1997
81. Lebowitz PF, Casey PJ, Prendergast GC, Thissen JA: Farnesyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J Biol Chem 272: 15591-15594, 1997
82. Tapon N, Hall A: Rho, Rac, and Cdc42 GTPases regulate the organization of the actin cytoskeleton. Curr Opin Cell Biol 9: 86-92, 1997
83. Du W, Liebowitz PF, Prendergast GC: Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated rhoB. Molec Cell Biol 19: 1831-1840, 1999
84. Maltese WA: Posttranslational modification of proteins by isoprenoids in mammalian cells. FASEB J 4:3319-3328, 1990
85. Seabra MC, Brown MS, Slaughter CA, Sudhof TC, Goldstein JL: Purification of component A of rab geranylgeranyl transferase: Possible identity with the chorideremia gene product. Cell 70: 1049-1057, 1992
86. Seabra MC, Goldstein JL, Sudhof TC, Brown MS: Rab geranylgeranyl transferase: A mutltisubunit enzyme that prenylates GTP-binding proteins terminating in Cys-X-Cys or Cys-Cys. J Biol Chem 267: 14497-14503, 1992
87. Lerner EC, Qian Y, Hamilton AD, Sebti SM: Disruption of oncogenic K-ras4B processing and signaling by a potent geranylgeranyltransferase inhibitor. J Biol Chem 270: 26770-26773, 1995
88. Miquel K, Pradines A, Sun J, Qian Y, Hamilton AD, Sebti SM, Favre G: GGTI-298 induces Go-GI block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57: 1846-1850, 1997
89. Sun J, Qian Y, Hamilton AD, Sebti SM: Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required to inhibit K-ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16: 1467-1473, 1998
90. Adnane I, Francisco A, Qian Y, Hamilton A, Sebti SM: p21 WAFIICIPI is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor P-Sp1 responsive element. Mol Cell Biol 18: 6962-6970, 1998
91. Sun J, Qian Y, Chen Z, Marfurt J, Hamilton AD, Sebti SM: The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of retinoblastoma and partner switching ofcyclin-dependent kinase inhibitors. J Biol Chem 274: 6930-6934, 1999
92. Elegbede JA, Elson CE, Tanner MA, Gould MN: Inhibition of DMBA-induced mammary cancer by monoterpene d-limonene. Carcinogenesis 5: 661-664, 1984
93. Elson CE, Maltzman TH, Boston JL, Tanner MA, Gould MN: Anti-carcinogenic activity of d-limonene during the initiation and promotion/progression stages of DMBA-induced rat mammary carcinogenesis. Carcinogenesis 9: 331-332, 1988
94. Maltzman TH, Hurt LM, Elson CE, Tanner MA, Gould MN: The prevention of nitrosomethylurea-induEed mammary tumors by d-limonene and orange oil. Carcinogenesis 10: 71(1783, 1989
95. Elegbede J, Maltzman TH, Elson CE, Gould MN: Effects of anticarcinogenic monoterpenes on Phase II hepatic metabolizing enzymes. Carcinogenesis 14: 1221-1223, 1993
96. Haag ID, Lindstrom MJ, Gould MN: Limonene-induced regression of mammary carcinoma. Cancer Res 52: 4021-4026, 1992
97. Crowell PL, Ren Z, Lin S, Vedejs E, Gould MN: Structure activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation. Biochem Pharmacol 47: 1405-1415, 1994
98. Hohl RJ, Lewis K: Differential effects of monoterpenes and lovastatin on ras porcessing. J Biol Chem 270: 17508-17512, 1995
99. Stayrook KR, McKinzie JH, Barbhaiya LH, Crowell PL: Effects of the antitumor agent perillyl alcohol on H-ras vs K-ras farnesylation and signal transduction. Anticancer Res 18: 823-828, 1998
100. Ren Z, Elson CE, Gould MN: Inhibition of type I and type II geranylgeranyl protein uansferases by the monoterpene perillyl alcohol in NIH3T3 cells. Biochem Pharmacol 54: 113-120, 1997
101. Ren Z, Gould MN: Inhibition of ubiquinone and cholesterol synthesis by the monoterpene perillyl alcohol. Cancer Lett 76: 185-190, 1994
102. Gelb MH, Tamanol F, Kohel Y, Ghomashchi F, Esson K, Gould M: The inhibition of protein prenyltransferses by oxygenated metabolites oflimonen and perillyl alcohol. Cancer Lett 91; 169-175, 1995
103. Hardcastle IR, Rowlands MG, Barber AM, Grimshaw RM, Mohan MK, Nutley BP, Jarman M: Inhibition of protein prenylation by metabolites of limonene. Biochem Pharmacol 57: 801-809, 1999
104. Aiazi EA, Satomi Y, Ellis MJ, Haag JD, Shi W, Sattler CA, Gould MN: Activation of the transforming growth factor P signaling pathway and inudction of cytostasis and apoptosis in mammary carcinomas treated with the anticancer agent perillyl alcohol. Cancer Res 59: 1917-1928, 1999
105. Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH: Phase I clinical trial of perillyl alcohol administered daily. Clin Cancer Res 4: 1159-1164, 1998
106. Ripple G, Gould R, Arzoomanian D, Alberti D, Feierabend C, Simon K, Morgan K, Tutsch K, Pomplun M, Wahamaki A, Mrnocha G, Bailey H: Phase I trial of perillyl alcohol administered four times a day. Proc Am Sec Clin Oncology 885, 1998
107. Budd GT, Elson PJ, Chan JM, Snyder JM, Ellis MJ, Banerjee S, McLain D, Hawk E, Ganapathi R: Single-dose phase I and pharmacokinetic trial ofperillyl alcohol (POH) as a chemopreventive for breast cancer. Proc Am Sec Clinical Oncol 714, 199
108. Mukhopadhyay T, Tainsky M, Cavendar AC, Roth JA: Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 51: 1744-1748, 1991
109. Shirasawa S, Furuse M, Yokoyama N, Sazuki T: Altered growth of human colon cancer cell lines disrupted at activated K-ras. Science 260: 85-87, 1993
110. Aoki K, Yoshida T, Sugimura T, Terada M: Liposome mediated transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine peritoneal cavity. Cancer Res 55: 3810-3816, 1995
111. Aoki K, Yoshida T, Matsumoto N, Ide H, Sugimura T, Terada M: Suppression of K-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with K-ras mutation but not those without Ki-ras mutation. Mol Carcinog 20: 251-258, 1997
112. Georges R, Mukhopadhyay T, Zhang Y, Yen N, Roth JA: Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 53: 1743-1746, 1993
113. Alemany R, Ruan S, Masafumi K, Koch PE, Mukhopadhyay T, Cristiano RJ, Roth RJ: Growth inhibitory effect of antiK-ras adenovirus on lung cancer cells. Cancer Gene Ther 3: 296301, 1996
114. Roth JA: Modification of mutant K-ras gene in nonsmall cell lung cancer (NSCLC). Hum Gene Ther 7: 875-889, 1996
115. Chang EH, Miller PS, Cushman C, Devadas K, Pirollo KF, Ts'O POP, Yu ZP: Antisense inhibition of ras p21 expression that is sensitive to point mutation. Biochem 30: 8283-8286, 1991
116. Monia BP, Johnston JE, Ecker DJ, Zounes MA, Lima WF, Freier SM: Selective inhibition of mutant Ha-ras mRNA expression by antisense oligonucleotides. J Biol Chem 267: 19954-19962, 1992
117. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E: Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res 53: 577-580, 1993
118. Wickstrom E: Antisense tumor therapy: Activated c-Ha-ras oncogene in the mouse. From Methods in Molecular Medicine: Antisense Therapeutics, Agrawal S (ed), Human Press, Totowa, NJ, pp 87-108, 1996
119. Schwab G, Chavny C, Duroux I, Goubin G, Lebeau J, Helene C, Saison-Behmoaras T: Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci 91: 10460-10464, 1994
120. Dorr A, Bruce J, Monia B, Johnston J, Geary R, Kwoh TJ, Holmlund J, Nemunaitis J: Phase I and pharmacokinetic trial of ISIS 2503, a 20-mer antisense oligonucleotide against H-ras by 14-day continuous infusion (CIV) in patients with advanced cancer. Proc Am Sec of Clinical Oncol 18(abs)603, 1999
121. Monia BP, Johnston JF, Geiger T, Muller M, Fabbro D: Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat Med 2: 668-675, 1996
122. Monia BP, Johnston JP, Geiger T, Muller M, Fabbro D: Antitumor iictivity ofa phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nature Med 5: 127 1999
123. Lau QC, Brusselbach S, Muller R: Abrogation of c-raf expression induces apoptosis in tumor cells. Oncogene 16: 1899-1902, 1998
124. Gokhale PC, McRae D, Monia BP, Bagg A, Rahman A, Dritschilo A, Kasid U: Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo. Antisense Nucleic Acid Drug Dev 9: 191-201, 1999
125. Bernhard E, Kao G, Cox A, Sebti S, Hamilton AD, Muschel RJ, McKenna WG: The farnesyltransferase inhibitor FIT-277 radiosensitizes H-ras transformed rat embryo fibroblasts. Cancer Res 56: 1727-1730, 1996
126. Heliez C, Delmas C, Bonnet J, Moyal E, End D, Daly-Schveitzer N, Favre G, Toulas C: farnesyltransferase inhibitor R115777 radiosensitizes human glioma cell lines. Proc Am Assoc Cancer Res 40: 640, 1999
127. Holmlund JT, Rudn CM, Mani S, Fleming GF, Stadler W, Kunkel K, Kwoh JT, Geary R, Dorr A, Ratain MJ: Phase I trial of ISIS 513UODN 698A a 20-mer phosphorothioate administered by a 24 hour weekly intravenous (iv) infusion to patients with advanced cancer. Proc Amer Sec Clinical Oncol 18; 605, 1999
128. O'Dwyer PJ, Stevenson JP, Gallagher M, Mitchell E, Friedland D, Rose L, Cassella A, Holmlund JT, Dean N, Dorr A, Geary R, Yao K-S: Phase I pharmacokinetic/pharmacodynamic trial of raf-1 antisense ODN (ISIS 5132, CGP-69846A). Proc Am Sec Clinical Oncol 17: 811, 1998
129. Dorr FA: Antisense therapy of cancer. Proc Dorr, FA. Antisense therapy of cancer. ProcEORTC Early Drug Development Meeting, 1999
130. Wood ER, Gilmer TM, Hunter BN, Keith BR, Lee AV, McDonald OB, Mullin RJ, Rusnak DW, Lackey KE: Biological effects of c-Rafl kinase inhibitors. Proc Am Assoc Cancer Res 40: 724, 1999
131. Cheung M, Glennon KC, Lackey KE, Peel MR: Preparation of arylmethylideneazaoxindoles as protein kinase inhibitors. Application WO 98-EP6357 981008.
132. Miller S, Osterhout M, Dumas J, Khire U, Lowinger TB, Riedl B, Scott WJ, Smith RA, Wood JE, Gunn D, Rodriguez M, Wang M: Inhibition of raf kinase using symetrical and unsymetrical substituted diphenyl urea. Application: WO 98-US26081 981222.
133. Hedge P, Boyle J, Thomas F: Benzamides as raf kinase inhibitors. Application: WO 97-GB3102 971112.
134. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci 92: 7686-7689, 1995
135. Favata MF, Horiuchi KY, Manes EJ, Daulerio AJ, Stradley DA, Feeser WS, Van Dyk DE, Pitts WJ, Earl RA, Hobbs F, Copeland RA, Magolda RL, Scherle PA, Trazkos JM: Identification of a novel inhibitor mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632, 1998
136. Sebolt-Leopold JS, Dudley DT, Herera R, Van Becelaere K, Wiland A, Gowan RC, Tecle H, Barrett SD, Bridges A, Przybranowski S, Leopold WR, Saltiel AR: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature Med 5: 810-816, 1999
137. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, Lee JC: SE 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin 1. FEES Lett 364: 229-233, 1995
138. Jackson JR, Bolognese B, Hillegass L, Kassis S, Adams J, Griswold DE, Winkler JD: Pharmacological effects of SE 220025, a slective inhibitor of p38 mitogen activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther 284: 687-692, 1998